Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02460224) enrolled a total of 512 participants across many different treatment groups. It was a two-phase study testing an experimental drug called LAG525, both on its own and combined with another drug called PDR001, in people with advanced cancer. Phase 1 aimed to find appropriate doses by looking at how many people experienced serious side effects early in treatment (called dose-limiting toxicities — that is, harmful reactions severe enough to limit how much drug could be given). Phase 2 then looked at how many participants' tumours responded to the combination treatment, measured using a standard set of imaging-based rules called RECIST 1.1. The reported data shows that in Phase 1, dose-limiting toxicities were uncommon across most dosing groups. Out of the groups where this was reported, only a small number of individuals experienced them — for example, 1 participant in the lowest single-agent dose group, 2 in another single-agent group, and 1 in one of the combination groups; the remaining groups reported zero dose-limiting toxicities. For Phase 2, the reported outcome measuring tumour response (called Overall Response Rate, or ORR — meaning the percentage of people whose tumour either disappeared completely or shrank by at least 30%) varied across cancer types and treatment groups. In the treatment-naïve group (people who had not previously received this type of treatment) receiving one dosing schedule, ORR figures ranged from approximately 14% to 26% depending on tumour type, while in the previously treated group the reported figures were generally lower, ranging from around 0% to 9%. Some figures for certain subgroups were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38336861) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Mesothelioma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- (Phase I part) You have an advanced or spreading solid tumour cancer that can or cannot be measured on scans, and your cancer has continued to grow despite standard treatment, you could not tolerate standard treatment, or no standard treatment exists for your cancer.
- (Phase II part) You have an advanced or spreading solid tumour cancer with at least one area that can be measured on scans, and your cancer has gotten worse after your most recent treatment.
- (Phase II part) Your cancer is one of the following types: non-small cell lung cancer (NSCLC), melanoma (skin cancer), kidney cancer, mesothelioma, or triple-negative breast cancer (TNBC).
- (Phase II part) You are generally well enough to carry out light activity and care for yourself, based on a standard fitness scoring system (confirm with trial site).
- (Phase II part) You have an area of cancer that a doctor can safely take a small tissue sample (biopsy) from, and you are able to have this procedure done.
Who may not be able to join:
- You have had a severe allergic reaction in the past to any ingredient in the study treatment or to similar types of medicines called monoclonal antibodies.
- You currently have, or are suspected to have, an active autoimmune disease (a condition where your immune system attacks your own body).
- You have an active infection that is currently being treated with antibiotic medicines given throughout your body (not just on the skin).
- You are living with HIV, or you have an active hepatitis B or hepatitis C infection.
- You are regularly taking steroid medicines (except for low "replacement" doses used to treat a condition called adrenal insufficiency).
- You are currently taking any medicines that suppress or weaken your immune system.
- You have received a live vaccine (a type of vaccine that uses a weakened form of a virus) within 4 weeks before starting the study treatment.
- You have received any cancer treatment that works throughout your whole body within 2 weeks before your first dose of the study treatment.
- You have cancer that has spread to your brain or spinal cord and is causing symptoms, or that requires targeted treatment to that area, or that has needed increasing doses of steroids in the past 2 weeks.
- You have a current lung inflammation (pneumonitis) or have had lung inflammation caused by a medicine in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs); Phase 2: Overall Response Rate (ORR) Per RECIST 1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.